Skip to Content

Xigduo XR Approval History

FDA Approved: Yes (First approved October 30, 2014)
Brand name: Xigduo XR
Generic name: dapagliflozin and metformin hydrochloride
Dosage form: Extended-Release Tablets
Company: AstraZeneca
Treatment for: Diabetes, Type 2

Xigduo XR (dapagliflozin and metformin hydrochloride) is a once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Xigduo XR

DateArticle
Oct 30, 2014Approval FDA Approves Xigduo XR (dapagliflozin and metformin hydrochloride) for Type 2 Diabetes

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide